An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients with Stargardt’s Macular Degeneration

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513501-31-00

Acronym

LTS13588

Enrollment

Registered

2024-08-13

Start date

2013-05-30

Completion date

Unknown

Last updated

2024-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital, hereditary and neonatal diseases

Brief summary

The incidence of Adverse Events

Detailed description

Clinically important changes in ocular safety assessments, Delay in retinal degeneration

Interventions

DRUGSAR422459

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The incidence of Adverse Events	—

Secondary

Measure	Time frame
Clinically important changes in ocular safety assessments, Delay in retinal degeneration	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026